Home » Stocks » LMDX

LumiraDx Limited (LMDX)

LumiraDx will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) 24.94M
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

LumiraDx, a UK-based provider of point-of-care diagnostics including COVID-19 tests, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

4 months ago - NASDAQ

LumiraDx Limited has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

A new rapid test for Covid-19 can return results in just 12 minutes, Health Minister Robin Swann has said.

4 months ago - The Irish News

LumiraDx, the next generation point-of-care diagnostic company, announced today that it has received Switzerland Federal Office of Public...

4 months ago - PRNewswire

About LMDX

LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity. We currently have four tests available on our Platform and a broad menu of tests in development. Our proprietary Platform is designed to simplify, scale down, and integrate multiple testing methodologies onto a single instrument a... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
Ron Zwanziger
Employees
1,022
Stock Exchange
NASDAQ
Ticker Symbol
LMDX
Full Company Profile